Yahoo Finance

Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

BOULDER, Colo., December 09, 2025--(BUSINESS WIRE)--Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s ...
Yahoo Finance

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

ENV-294 is a clinical-stage small molecule designed to address the shared pathways underlying multiple inflammatory conditions via a first-in-class mechanism. ENV-294 entered Phase 1 studies in ...
Morningstar

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory ...

Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that the US ...